» Articles » PMID: 35746764

SARS-CoV-2 Viral Load in the Pulmonary Compartment of Critically Ill COVID-19 Patients Correlates with Viral Serum Load and Fatal Outcomes

Overview
Journal Viruses
Publisher MDPI
Specialty Microbiology
Date 2022 Jun 24
PMID 35746764
Authors
Affiliations
Soon will be listed here.
Abstract

While SARS-CoV-2 detection in sputum and swabs from the upper respiratory tract has been used as a diagnostic tool, virus quantification showed poor correlation to disease outcome and thus, poor prognostic value. Although the pulmonary compartment represents a relevant site for viral load analysis, limited data exploring the lower respiratory tract is available, and its association to clinical outcomes is relatively unknown. Using bronchoalveolar lavage (BAL) and serum samples, we quantified SARS-CoV-2 copy numbers in the pulmonary and systemic compartments of critically ill patients admitted to the intensive care unit of a COVID-19 referral hospital in Croatia during the second and third pandemic waves. Clinical data, including 30-day survival after ICU admission, were included. We found that elevated SARS-CoV-2 copy numbers in both BAL and serum samples were associated with fatal outcomes. Remarkably, the highest and earliest viral loads after initiation of mechanical ventilation support were increased in the non-survival group. Our results imply that viral loads in the lungs contribute to COVID-19 disease severity, while blood titers correlate with lung virus titers, albeit at a lower level. Moreover, they suggest that BAL SARS-CoV-2 copy number quantification at ICU admission may provide a predictive parameter of clinical COVID-19 outcomes.

Citing Articles

Uncovering the Contrasts and Connections in PASC: Viral Load and Cytokine Signatures in Acute COVID-19 versus Post-Acute Sequelae of SARS-CoV-2 (PASC).

Compeer B, Neijzen T, Van Lelyveld S, Martina B, Russell C, Goeijenbier M Biomedicines. 2024; 12(9).

PMID: 39335455 PMC: 11428903. DOI: 10.3390/biomedicines12091941.


Ethanol Inhalation as a Method to Denature the Spike Protein of SARS-CoV-2.

Manning T, Livingston T, Persaud C, Patel A, Adair M, Taylor T Adv Exp Med Biol. 2024; 1457:45-77.

PMID: 39283420 DOI: 10.1007/978-3-031-61939-7_3.


Serum cytokine dysregulation signatures associated with COVID-19 outcomes in high mortality intensive care unit cohorts across pandemic waves and variants.

Maass H, Ynga-Durand M, Milosevic M, Krstanovic F, Matesic M, Zuza I Sci Rep. 2024; 14(1):13605.

PMID: 38871772 PMC: 11176334. DOI: 10.1038/s41598-024-64384-y.


Evaluation of the Neutralizing Antibody STE90-C11 against SARS-CoV-2 Delta Infection and Its Recognition of Other Variants of Concerns.

Abassi L, Bertoglio F, Macak Safranko Z, Schirrmann T, Greweling-Pils M, Seifert O Viruses. 2023; 15(11).

PMID: 38005829 PMC: 10675157. DOI: 10.3390/v15112153.


Differential activation of programmed cell death in patients with severe SARS-CoV-2 infection.

Riegler A, Benson P, Long K, Leal Jr S Cell Death Discov. 2023; 9(1):420.

PMID: 37985756 PMC: 10662024. DOI: 10.1038/s41420-023-01715-4.


References
1.
Hagman K, Hedenstierna M, Gille-Johnson P, Hammas B, Grabbe M, Dillner J . Severe Acute Respiratory Syndrome Coronavirus 2 RNA in Serum as Predictor of Severe Outcome in Coronavirus Disease 2019: A Retrospective Cohort Study. Clin Infect Dis. 2020; 73(9):e2995-e3001. PMC: 7499508. DOI: 10.1093/cid/ciaa1285. View

2.
McGonagle D, Bridgewood C, Meaney J . A tricompartmental model of lung oxygenation disruption to explain pulmonary and systemic pathology in severe COVID-19. Lancet Respir Med. 2021; 9(6):665-672. PMC: 8121498. DOI: 10.1016/S2213-2600(21)00213-7. View

3.
. Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States. Nat Med. 2020; 26(6):861-868. DOI: 10.1038/s41591-020-0877-5. View

4.
Cheng P, Wu H, Yang J, Song X, Xu M, Li B . Pneumonia scoring systems for severe COVID-19: which one is better. Virol J. 2021; 18(1):33. PMC: 7874994. DOI: 10.1186/s12985-021-01502-6. View

5.
Gandhi R, Lynch J, Del Rio C . Mild or Moderate Covid-19. N Engl J Med. 2020; 383(18):1757-1766. DOI: 10.1056/NEJMcp2009249. View